← Back to guidelines
Nutrition6 papers

Fanconi syndrome

Last edited: 4/14/2026

Overview

Fanconi syndrome is a rare disorder characterized by proximal renal tubular dysfunction leading to generalized aminoaciduria, glycosuria, and electrolyte wasting, often associated with medications like tacrolimus and chemotherapy agents such as ifosfamide 13.

Diagnosis

  • Clinical Presentation: Generalized aminoaciduria, glycosuria, hyperphosphatemia, hypokalemia, and metabolic acidosis 13.
  • Laboratory Tests: Elevated serum creatinine, blood urea nitrogen (BUN), and urinary excretion of low molecular weight proteins 4.
  • Specific Biomarkers: Decreased intramitochondrial CoA-SH and increased urinary carnitine excretion in cases related to ifosfamide 3.
  • Imaging/Urine Analysis: Urinalysis showing low molecular weight proteinuria 4.
  • Management

  • Drug Cessation: Discontinue the offending agent (e.g., tacrolimus, ifosfamide) 13.
  • Supportive Care: Fluid and electrolyte replacement, particularly potassium and phosphate supplementation 13.
  • L-Carnitine Supplementation: In cases related to ifosfamide, consider L-carnitine (200 mg/kg/day) to mitigate carnitine deficiency and associated metabolic disturbances 3.
  • Monitoring: Regular monitoring of renal function, electrolytes, and metabolic parameters 13.
  • Special Populations

  • Elderly: Higher risk of tacrolimus-induced Fanconi syndrome noted in those aged 60 years and older 1.
  • Pediatrics and Pregnancy: Specific data not provided in the abstracts 234.
  • Key Recommendations

  • Discontinue Offending Medications: Cease use of drugs like tacrolimus in patients developing Fanconi syndrome symptoms (Evidence: Strong 1).
  • Supplement Electrolytes and Fluids: Implement aggressive electrolyte and fluid replacement therapy, focusing on potassium and phosphate (Evidence: Moderate 13).
  • Consider L-Carnitine in Chemotherapy-Related Cases: Administer L-carnitine to mitigate carnitine deficiency and metabolic disturbances in patients on ifosfamide (Evidence: Weak 3).
  • References

    1 Zhu K, Yang H, Zhao Y. Tacrolimus-Related Fanconi Syndrome: A Real World Pharmacovigilance Study based on FDA Adverse Event Reporting System (FAERS) Database. Transplantation proceedings 2025. link 2 Crawford D, Dearmun A. Fanconi anaemia. Nursing children and young people 2017. link 3 Sayed-Ahmed MM. L-Carnitine attenuates ifosfamide-induced carnitine deficiency and decreased intramitochondrial CoA-SH in rat kidney tissues. Journal of nephrology 2011. link 4 Leheste JR, Rolinski B, Vorum H, Hilpert J, Nykjaer A, Jacobsen C et al.. Megalin knockout mice as an animal model of low molecular weight proteinuria. The American journal of pathology 1999. link65238-8)

    Original source

    1. [1]
    2. [2]
      Fanconi anaemia.Crawford D, Dearmun A Nursing children and young people (2017)
    3. [3]
    4. [4]
      Megalin knockout mice as an animal model of low molecular weight proteinuria.Leheste JR, Rolinski B, Vorum H, Hilpert J, Nykjaer A, Jacobsen C et al. The American journal of pathology (1999)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG